Posted by Michael Wonder on 01 Mar 2025
Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis
28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first and only treatment approved by Health Canada for eligible patients with active psoriatic arthritis or ankylosing spondylitis that inhibits two key inflammatory cytokines, IL-17A and IL-17F.
UCB Canada is pleased to announce that following the positive reimbursement recommendations from Canada's Drug Agency (CDA, formerly the Canadian Agency for Drugs and Technologies in Health/CADTH) and the Institut National d'Excellence en Santé et en Services Sociaux (INESSS), UCB Canada has successfully concluded negotiations with pCPA (pan Canadian Pharmaceutical Alliance).
